A Single Part, Open-Label, Randomised, Three-Way Crossover Study Designed to Evaluate the Pharmacokinetic Parameters and Relative Bioavailability of Sorafenib From Sorafenib (XS005) Tablets and Capsules Compared With Nexavar® (Reference Product) in Healthy Male Subjects
Latest Information Update: 10 Sep 2024
At a glance
- Drugs Sorafenib (Primary)
- Indications Cancer
- Focus Pharmacokinetics
- Sponsors Xspray Pharma
Most Recent Events
- 06 Sep 2024 Results published in the Xspray Pharma Media Release
- 06 Sep 2024 According to Xspray Pharma media release, data from this study published in the US journal Clinical Pharmacology in Drug Development
- 08 Aug 2023 New trial record